drugset
drugset / Trial / NCT01027923

IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)

NCT01027923 ↗

Phase 1 Terminated 6 enrolled Washington University School of Medicine
RandomizedParallel-groupOpen-labelTreatment

Summary

In this phase I extension study, the investigators seek to test the safety of both higher doses of plerixafor as well as intravenous dosing to maximize inhibition of the target, CXCR4.

Timeline

Start
2010-05
Primary completion
2010-07
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Plerixafor Small molecule 320 ug/kg Intravenous
Subject Plerixafor Small molecule 420 ug/kg Intravenous
Subject Plerixafor Small molecule 560 ug/kg Intravenous
Background Cytarabine Small molecule 1000 mg/m2 Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous
Background Mitoxantrone Small molecule 8 mg/m2 Intravenous

Indications

acute myeloid leukemia